Developer of biopharmaceutical technology intended to address the correction of the nonsense mutations. The company's technology develops a suppressor tRNA delivery to treat nonsense mutations, helping lung cells to override premature stop signals and make full-length, functional CFTR protein, enabling patients to avail medicines for genetic respiratory diseases.